A Phase 1 Open‐Label, Fixed‐Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects

This pharmacokinetic (PK) drug‐interaction trial investigated the effects of repeated dosing of a plant‐derived pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex in the United States and Epidyolex in Europe; 100 mg/mL oral solution) on caffeine clearance via modulation of cyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Thai, Ching, Tayo, Bola, Critchley, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596598/
https://www.ncbi.nlm.nih.gov/pubmed/33951339
http://dx.doi.org/10.1002/cpdd.950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596598/
https://www.ncbi.nlm.nih.gov/pubmed/33951339
http://dx.doi.org/10.1002/cpdd.950

Ejemplares similares